Middle East & Africa Organoids Market Report (2021-2031) by Scope, Segmentation, Dynamics, and Competitive Analysis

The Middle East & Africa organoids market size is expected to reach US$ 289.76 million by 2031 from US$ 77.94 million in 2023. The market is estimated to record a CAGR of 17.8% from 2023 to 2031.

Executive Summary and Middle East & Africa Organoids Market Analysis:

The Middle East & Africa organoids market is segmented into the UAE, South Africa, Saudi Arabia, and the Rest of Middle East & Africa. The regional growth is attributed to the burgeoning research on cancer and gene mutations, the increasing popularity of the disease modeling approach, and developments by market players offering organoids.

Middle East & Africa Organoids Market Strategic Insights

Get more information on this report Request Free Sample PDF

Middle East & Africa Organoids Market Segmentation Analysis

Key segments that contributed to the derivation of the Middle East & Africa organoids market analysis are type, application, source, offering, and method.

• Based on type, the Middle East & Africa organoids market is segmented into intestine, liver, stomach, pancreas, lung, brain, kidney, and others. The intestine held the largest share of the market in 2023.
• Based on application, the Middle East & Africa organoids market is segmented into developmental biology disease, pathology of infectious disease, regenerative medicine, drug toxicity and efficacy testing, drug discovery and personalized medicine, and others. The developmental biology disease held the largest share of the market in 2023.
• Based on source, the Middle East & Africa organoids market is bifurcated into pluripotent stem cells and organ-specific adult stem cell. The pluripotent stem cells held a larger share of the market in 2023.
• Based on offering, the Middle East & Africa organoids market is segmented into instruments, consumables, and services. The consumables held the largest share of the market in 2023. The instruments segment is further sub segmented into devices and equipment. The consumables segment is further sub segmented into sensors and others.
• Based on method, the Middle East & Africa organoids market is segmented into micropatterned plates, ultralow attachment plates, hanging drop, microdroplet or emulsion, and others. The hanging drop held the largest share of the market in 2023.

Middle East & Africa Organoids Market Outlook

Organoids are microscopic and self-organized 3D structures derived in vitro from stem cells. They exhibit various structural and functional characteristics of their in vivo counterpart organs. This multipurpose technology has led to numerous new human cancer models. It is now possible to create indefinitely expanding organoids starting from the tumor tissue of individuals suffering from a variety of cancers. Alternatively, CRISPR-based gene modification allows the creation of cancer organoid models by introducing any combination of cancer gene modifications to normal organoids. Tumor organoids, when combined with immune cells and fibroblasts, generate a cancer microenvironment model that enables immune-oncology applications. Recent studies emphasize the significant role of organoids in personalized medicine approaches. Continuous advancements in organoid technology have enabled tumors and patient-centric 3D cultures of cells isolated from tumor biopsies. Organoids have been generated from breast, bladder, colon, prostate, pancreas, and liver cancer in humans over the past few decades. Studies involving these models help provide a clear overview of these malignancies. Tumoroid lines being introduced in vitro are opening new avenues for a range of downstream applications such as drug discovery and development and cancer research. Moreover, 3D-based cultures offer added advantages over conventional 2D cancer-derived cell lines.

Recent research and development activities have indicated that tumoroid culturing is highly effective in allowing the collection of various cancer subtypes from a large group of patients. As organoids can be easily derived and expanded from single cancer cells, organoids are increasingly being introduced into applications to mimic intratumor differentiation in culture. Companies have been developing innovative biobanks for storing several biological samples, including tumors. For instance, OrganoidBase (developed by Crown Bioscience) consists of 342 tumor organoid models derived from patient-derived xenograft (PDX) models [i.e., PDX-derived organoids (PDXOs)]. PDXOs offer detailed information on histopathology, IC50, genomic, and transcriptomic analysis data associated with drug response; it also has an additional 217 models from primary patient samples. These PDXO models have varied indications, with multiple models derived from over 20 organ and tissue types. Crown Biosciences commercializes organoids in a 3D in vitro model derived using IP-protected Hubrecht Organoid Technology (HUB) protocols. Thus, the increasing demand for tumor modeling and biobanking fuels the organoids market growth.

Middle East & Africa Organoids Market Country Insights

Based on country, the Middle East & Africa organoids market comprises Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. Saudi Arabia held the largest share in 2023.

In recent times, regenerative medicine and organoids have been studied for their potential to treat chronic diseases as well as to provide better treatments and a potential cure for metabolic diseases and cancer using cellular therapies. Government initiatives and increasing collaborations among key players and research institutes are further likely to boost the adoption and acceptance of organoid treatments in Saudi Arabia. Saudi Arabia became the first country in the Arab world to register more than 10,000 stem cell donors in 2015. Since then, the country has experienced growth in stem cell donation, promoting the applications of organoids in the kingdom. The awareness campaigns were intended to raise awareness of the donor's role in saving people's lives with chronic conditions. The Saudi Center for Organ Transplantation and the Middle East Society for Organ Transplantation has reported an urgent need for organ transplantations in the region; such demands are expected to offer significant opportunities to the organoid market growth in the country.

According to the article "Awareness of Colorectal Cancer in Saudi Arabia: Cross-Sectional Study," published in 2021, the country records a death rate of 8.3% due to colorectal cancer. Stem cell research can be employed to introduce solutions to prevent and treat chronic illnesses during the development phase. Therefore, increasing R&D activities in stem cell therapies with the rising number of cases of multiple sclerosis, atherosclerosis, and cancer is likely to favor the expansion of the organoids market in Saudi Arabia in the coming years.

Strategic initiatives such as partnerships by companies to expand research capabilities are projected to drive innovations in Saudi Arabia, which will eventually fuel the growth of the organoids market.

Middle East & Africa Organoids Market Report Highlights

Middle East & Africa Organoids Market Company Profiles

Some of the key players operating in the market STEMCELL Technologies Inc; Molecular Devices, LLC.; Hubrecht Organoid Technology; Definigen; Organoid Therapeutics; Thermo Fisher Scientific Inc; Corning Inc; Merck KGaA; InSphero; ACRO Biosystems; Bio-Techne Corp; SUN bioscience SA; ORGANOID SCIENCES Co., Ltd.; Crown Bioscience Inc; Sartorius AG; 3D Biotek LLC; Prellis Biologics Inc.; 3Dnamics Inc.; and Cellesce Ltd, among others. These players are adopting various strategies such as expansion, product innovation, and mergers and acquisitions to provide innovative products to their consumers and increase their market share.

Middle East & Africa Organoids Market Research Methodology :

The following methodology has been followed for the collection and analysis of data presented in this report:

• Secondary Research

The research process begins with comprehensive secondary research, utilizing both internal and external sources to gather qualitative and quantitative data for each market. Commonly referenced secondary research sources include, but are not limited to:

• Company websites, annual reports, financial statements, broker analyses, and investor presentations.
• Industry trade journals and other relevant publications.
• Government documents, statistical databases, and market reports.
• News articles, press releases, and webcasts specific to companies operating in the market.

Note: All financial data included in the Company Profiles section has been standardized to USD. For companies reporting in other currencies, figures have been converted to USD using the relevant exchange rates for the corresponding year.

• Primary Research

The Insight Partners conducts a significant number of primary interviews each year with industry stakeholders and experts to validate its data analysis and gain valuable insights. These research interviews are designed to:

• Validate and refine findings from secondary research.
• Enhance the expertise and market understanding of the analysis team.
• Gain insights into market size, trends, growth patterns, competitive dynamics, and future prospects.

Primary research is conducted via email interactions and telephone interviews, encompassing various markets, categories, segments, and sub-segments across different regions. Participants typically include:

• Industry stakeholders: Vice Presidents, business development managers, market intelligence managers, and national sales managers
• External experts: Valuation specialists, research analysts, and key opinion leaders with industry-specific expertise

Middle East & Africa Organoids Market Country and Regional Insights